TITLE

ALIMERA SUBMITS ILUVIEN NDA FOR DIABETIC MACULAR EDMA

PUB. DATE
August 2010
SOURCE
Worldwide Biotech;Aug2010, Vol. 22 Issue 8, p6
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article focuses on a new drug application (NDA) submitted by Alimera Sciences Inc. to the U.S. Food and Drug Administration (FDA) for its Iluvien flucocinolone acetonide intravitreal insert for diabetic macular edema (DME) treatment. A priority review is being requested by the company, which may prompt the FDA to release an action letter in the fourth quarter of 2010. According to Dan Myers, president and chief executive officer (CEO) of Alimera, Iluvien will serve as an alternative to the traditional multiple corticosteroid injections.
ACCESSION #
52570946

 

Related Articles

  • pSivida Corp. Reports Alimera's Intention to Resubmit Application to FDA for ILUVIEN(r) in DME Using Data from Completed Trials.  // Biomedical Market Newsletter;8/7/2012, Vol. 21, p1 

    The article offers information on the plans of Alimera Sciences Inc. related with resubmission of drug application to the U.S. Food and Drug Administration (FDA) for approval of the drug, Iluvien in treatment of diabetic macular edema (DME). Several issues have been raised by the FDA on phase...

  • FDA Approves Lucentis(r) (Ranibizumab Injection) for Treatment of Diabetic Macular Edema (DME).  // Biomedical Market Newsletter;8/15/2012, Vol. 21, p1 

    The article offers information that the U.S. Food & Drug Administration (FDA) has approved the drug Lucentis for the treatment of Diabetic Macular Edema (DME). Diabetes is the major cause of new cases of blindness in the adults in the U.S. and DME is estimated to affect more than 560,000...

  • Alimera resubmits NDA for intravitreal insert.  // Ophthalmology Times;6/1/2011, Vol. 36 Issue 11, p3 

    The article reports on Alimera Sciences Inc.'s resubmission of the new drug application (NDA) for an investigational intravitreal insert containing fluocinolone acetone (Iluvien) to the U.S. Food and Drug Administration (FDA).

  • FDA Seeks More Data on Iluvien Studies.  // Review of Ophthalmology;Feb2011, Vol. 18 Issue 2, p7 

    The article reports on the Complete Response Letter (CRL) received by Alimera Sciences Inc. from the U.S. Food and Drug Administration regarding Alimera's New Drug Application for the investigational drug Iluvien.

  • Alimera Moves Forward With Iluvien Review.  // Review of Ophthalmology;May2014, Vol. 21 Issue 5, p9 

    The article reports that the drug firm Alimera Sciences Inc. has resubmitted the New Drug Application (NDA) for Iluvien, a treatment for Diabetic Macular Edema (DME), to the U.S. Food and Drug Administration (FDA) for review, as of May 2014 and presents views of Dan Myers of Alimera on the NDA.

  • IV Triamcinolone and Ozurdex: The Evidence. Chiang, Allen; Haller, Julia A. // Review of Ophthalmology;Sep2010, Vol. 17 Issue 9, p66 

    The article mentions that intravitreal triamcinolone acetonide and dexamethasone implant (Ozurdex) were approved by the U.S. Food and Drug Administration (FDA) for treatment of macular edema due to branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO). It cites the...

  • Germany : Aflibercept Solution for Injection into the Eye Receives FDA Approval for the Treatment of Diabetic Macular Edema (DME).  // TendersInfo News;7/31/2014, p1 

    The article informs that the U.S. Food and Drug Administration (FDA) has approved aflibercept solution for injection into the eye (EYLEA) for the treatment of diabetic macular edema (DME) in the U.S. as of July 2014. It reports that the Aflibercept solution for injection has already been...

  • FDA seeks more data for FA insert. Groves, Nancy // Ophthalmology Times;12/1/2011, Vol. 36 Issue 23, p1 

    The article reports on the delay of the approval of Alimera Sciences Inc.'s investigational fluocinolone acetonide (FA) intravitreal insert (Iluvien) by the U.S. Food Drug Administration (FDA). It states that the drug is developed to treat diabetic macular edema (DME) associated with diabetic...

  • Other News To Note.  // BioWorld Today;10/21/2013, Vol. 24 Issue 202, p3 

    This section offers news briefs on the pharmaceutical industry. Alimera Sciences Incorporated of Atlanta, Georgia has received its third complete response letter from the U.S. Food and Drug Administration (FDA) for the drug application for Iluvien. Avexis Incorporated and Biolife Science Limited...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics